The content on this site is intended for healthcare professionals only
Dr Michele Maio talks with ecancer at the 2013 European Cancer Congress in Amsterdam about the survival analysis of a phase III study of ipilimumab and dacarbazine in metastatic melanoma
The results of this study, with 5 years of follow up, continue to demonstrate a long-term survival benefit for patients treated with ipilimumab plus DTIC compared to placebo plus DTIC. Consistent with the results of phase II studies, survival rates appear to plateau beginning at 3 years.
Dr Keith Flaherty provides additional commentary on the study
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
PD-1–refractory advanced melanoma: how do we get to the finish line?
Highlights in melanoma from ASCO 2024
Melanoma outcomes improved by dual immunotherapy before surgery rather than after
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma
